E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Other Biochemical Tests
Harry P. Selker,Robert J. Zalenski,Elliott M. Antman,Tom P. Aufderheide,Sheilah Bernard,Robert O. Bonow,W. Brian Gibler,Michael D Hagen,Paula A. Johnson,Joseph Lau,Robert A McNutt,Joseph P. Ornato,J. Sanford Schwartz,Jane D. Scott,Paul A. Tunick,W. Douglas Weaver +15 more
TL;DR: An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: A report from a National Heart Attack Alert Program Working Group.
Journal ArticleDOI
Saving and Improving Lives in the Information Age: Presidential Address at the American Heart Association 2014 Scientific Sessions.
TL;DR: The American Heart Association’s clinicians, scientists, lay volunteers, and staff are inspired by your dedication to saving and improving lives and have an unprecedented opportunity to harness these advances to save and improve lives.
Journal ArticleDOI
Ideal Cardiovascular Health in Former Smokers.
TL;DR: For example, this paper found that former smokers had higher burden of prevalent cardiovascular disease, hypertension, diabetes mellitus, and hypercholesterolemia compared to current and never smokers.
Journal ArticleDOI
Aging of intracoronary thrombus due to delayed time-to-reperfusionsincreases ischemic and angiographic complications in acute myocardial infarction
Satvendra Giri,Michael Gibson,Andrew C. Eisenhauer,Richard E. Kuntz,Campbell Rogers,Sabina A. Murphy,Joseph F. Mitchel,Elliott M. Antman,Daniel I. Simon +8 more
Journal Article
Abstract 11748: Edoxaban versus Warfarin in Patients at Increased Risk of Falling - A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial
Jan Steffel,Robert P. Giugliano,Eugene Braunwald,Sabina A. Murphy,Michele Mercuri,Youngsook Choi,Elliott M. Antman,Christian T. Ruff +7 more
TL;DR: Patients at increased risk of falling are a high-risk subgroup, with an increased risk for both stroke/SEE as well as for bleeding, and demonstrate consistent efficacy and safety with edoxaban as compared to well-managed warfarin.